StreetAlpha.app
Home › Stocks › TGTX

TG Therapeutics, Inc. (TGTX)

Healthcare
$63.34
▼ −2.37%
LAST CLOSE · NOV 20

TG Therapeutics develops and sells BRIUMVI, a treatment for multiple sclerosis, to physicians and patients. It last closed at $63.34 on Nov 20, down 2.37% on the day. The next earnings report for TGTX is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, TGTX reported EPS of $0.35 on revenue of $259.9M, with revenue up 60.7% from a year ago. Over its last 8 reports the stock moved an average of 10.8% the session after earnings. Over the last 12 months TGTX insiders bought $0 of stock on the open market and sold $438K, according to SEC Form 4 filings.

AI Auto Pilots
Is TGTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TGTX.

Key Stats

Last 12 months
Results
Revenue
$897.8M
+68.8% vs a year ago
Net income
$106.1M
−76.3% vs a year ago
EPS (diluted)
$0.67
−75.8% vs a year ago
Free cash flow
$85.6M
9.5% margin
Valuation
Market cap
$9.6B
151.1M shares
P/E
94.5
Price over 12 month EPS
Price to sales
10.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$429.4M
At Sep 30
Debt
$745.6M
At Sep 30
Shareholder equity
$572.1M
Shares outstanding
151.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.7M$6.7MFY2021FY2022: $2.8M$2.8MFY2022FY2023: $233.7M$233.7MFY2023FY2024: $329.0M$329.0MFY2024FY2025: $616.3M$616.3MFY2025

From TGTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
$0.35
Quarter ended Sep 2026
Year ago EPS
$2.43
−85.6% on a GAAP basis
Revenue
$259.9M
+60.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.15Dec '24Mar 2025: $0.03Mar '25Jun 2025: $0.17Jun '25Sep 2025: $2.43Sep '25Dec 2025: $0.15Dec '25Mar 2026: $0.12Mar '26Jun 2026: $0.05Jun '26Sep 2026: $0.35Sep '26Latest $0.35
Revenue by quarter
Dec 2024: $108.2MDec '24Mar 2025: $120.9MMar '25Jun 2025: $141.1MJun '25Sep 2025: $161.7MSep '25Dec 2025: $192.6MDec '25Mar 2026: $204.9MMar '26Jun 2026: $240.3MJun '26Sep 2026: $259.9MSep '26Latest $259.9M
How TGTX moved after its last 8 reports
Average move the session after a report ±10.8%
Nov 9, 2026Time not announced+5.9%
Aug 3, 2026Time not announced−11.3%
May 6, 2026Time not announced+16.3%
Feb 26, 2026Time not announced+4.2%
Nov 3, 2025Time not announced−3.1%
Aug 4, 2025Time not announced−18.0%
May 5, 2025Time not announced−13.3%
Mar 3, 2025Time not announced+14.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TGTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TGTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TGTX

Technical Analysis

TGTX · as of the Nov 20 close · updated each morning
Uptrend

The stock is 3% above its 20 day and 9% above its 50 day average. It is 27% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the Pivot S1 at $62.42, and the nearest resistance the swing high (Nov 2) at $63.60.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 4.8%/day
Key levels
$68.0352 week high+7.4%
$64.95Pivot R1+2.5%
$64.03Pivot+1.1%
$63.60Swing high (Nov 2)+0.4%
$63.34Last close
$62.42Pivot S1−1.5%
$61.5220 day average−2.9%
$61.50Swing low (Nov 17)−2.9%
$57.5850 day average−9.1%
$55.58100 day average−12.3%
$46.25200 day average−27.0%
$26.7652 week low−57.8%
Indicators
RSI (14)57.18Middle of its rangeNeutral
MACD2.27Above its signal lineBullish
Stochastic75.8Middle of its rangeNeutral
ADX (14)22.8Weak trend
Williams %R-34.9Oversold below −80, overbought above −20Neutral
CCI (20)65.8Oversold below −100, overbought above 100Neutral
Rate of change+5.9%Change over 10 sessionsBullish
ATR (14)$3.05Typical daily range, 4.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for TGTX

What happened before

See how TGTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TGTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TGTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TGTXHow many large options trades hit TGTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

TGTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲243 buying vs 183 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +26
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding457431+6.0%
In funds' top 1097+28.6%
Held by funds77.1%73.6%+3.6 pts
New / increased76 / 167101 / 149−2.8%
Reduced / sold out136 / 47122 / 36+15.8%
Put/call ratio0.260.61−57.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TGTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TGTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$438K2 sales · 2 insiders
2026-09 sold $275KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 10Laurence N CharneyDirectorSale5,000$54.96$275K
Nov 24, 2025Yann EchelardDirectorSale5,000$32.57$163K
Sep 11, 2025Sagar LonialDirectorSale20,852$32.24$672K
Jun 13, 2025Yann EchelardDirectorSale10,000$36.94$369K
Jan 6, 2025Sean A PowerCFOSale21,358$29.46$629K
Nov 11, 2024Laurence N CharneyDirectorSale25,000$30.20$755K
Every insider buy and sale for TGTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TGTX insider trades →

From SEC Form 4 filings by TGTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TGTX is in one of them and how their past TGTX trades turned out.

TGTX in the AI portfolios
Loading…

TGTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TGTX in an article yet. Here's the latest on the wider market.

TGTX in the news

TGTX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 6
Who traded TGTX · since 2020
Latest 1 filing
Christopher JacobsSell (partial)
$1K – $15KTraded Sep 8, 2020Filed Nov 6, 2020
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell (partial)$1K – $15KSep 8, 2020Nov 6, 202059 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About TG Therapeutics

TG Therapeutics is a biotechnology company that develops and sells treatments for diseases driven by B cells, with its main focus on multiple sclerosis. Its approved product, BRIUMVI, is a monoclonal antibody given as an infusion lasting about an hour every 24 weeks to adults with relapsing forms of multiple sclerosis. Its customers include physicians and patients in the United States, and a commercial partner sells the treatment in several other countries. The company is based in Morrisville, North Carolina.

Headquarters
New York, NY